These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25885574)

  • 1. A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
    Kümler I; Balslev E; Stenvang J; Brünner N; Nielsen D
    BMC Cancer; 2015 Feb; 15():78. PubMed ID: 25885574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.
    Kümler I; Balslev E; Stenvang J; Brünner N; Ejlertsen B; Jakobsen EH; Nielsen DL
    BMC Cancer; 2019 Jun; 19(1):573. PubMed ID: 31196001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
    Nygård SB; Vainer B; Nielsen SL; Bosman F; Tejpar S; Roth A; Delorenzi M; Brünner N; Budinska E
    Clin Cancer Res; 2016 Apr; 22(7):1621-31. PubMed ID: 26542057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
    Jandu H; Aluzaite K; Fogh L; Thrane SW; Noer JB; Proszek J; Do KN; Hansen SN; Damsgaard B; Nielsen SL; Stougaard M; Knudsen BR; Moreira J; Hamerlik P; Gajjar M; Smid M; Martens J; Foekens J; Pommier Y; Brünner N; Schrohl AS; Stenvang J
    BMC Cancer; 2016 Jan; 16():34. PubMed ID: 26801902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.
    Nygård SB; Christensen IJ; Nielsen SL; Nielsen HJ; Brünner N; Spindler KL
    Scand J Gastroenterol; 2014 Jan; 49(1):84-91. PubMed ID: 24256029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
    Palshof JA; Høgdall EV; Poulsen TS; Linnemann D; Jensen BV; Pfeiffer P; Tarpgaard LS; Brünner N; Stenvang J; Yilmaz M; Nielsen DL
    BMC Cancer; 2017 Jan; 17(1):48. PubMed ID: 28077117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
    Kümler I; Brünner N; Stenvang J; Balslev E; Nielsen DL
    Breast Cancer Res Treat; 2013 Apr; 138(2):347-58. PubMed ID: 23512247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer.
    Kümler I; Balslev E; Poulsen TS; Nielsen SL; Nygård SB; Rømer MU; Christensen IJ; Høgdall E; Moreira J; Nielsen DL; Brünner N; Stenvang J
    Int J Cancer; 2015 Oct; 137(8):2000-6. PubMed ID: 25855483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.
    Segar JM; Reed D; Stopeck A; Livingston RB; Chalasani P
    Oncologist; 2019 Dec; 24(12):1512-e1267. PubMed ID: 31383812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
    Hayashi H; Tsurutani J; Satoh T; Masuda N; Okamoto W; Morinaga R; Terashima M; Miyazaki M; Okamoto I; Nishida Y; Tominaga S; Tokunaga Y; Yamaguchi M; Sakamoto J; Nakayama T; Nakagawa K
    Breast Cancer; 2013 Apr; 20(2):131-6. PubMed ID: 22124996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
    Awada A; Garcia AA; Chan S; Jerusalem GH; Coleman RE; Huizing MT; Mehdi A; O'Reilly SM; Hamm JT; Barrett-Lee PJ; Cocquyt V; Sideras K; Young DE; Zhao C; Chia YL; Hoch U; Hannah AL; Perez EA;
    Lancet Oncol; 2013 Nov; 14(12):1216-25. PubMed ID: 24095299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
    Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
    J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
    Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
    Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
    Hochster HS; Uboha N; Messersmith W; Gold PJ; ONeil BH; Cohen D; Denlinger C; Cohen S; Leichman CG; Leichman L; Lenz HJ
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):17-23. PubMed ID: 25322874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.
    Amzerin M; Mokrim M; Errihani H; Piccart MJ
    J Med Case Rep; 2015 Feb; 9():5. PubMed ID: 25971303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
    Rolle CE; Kanteti R; Surati M; Nandi S; Dhanasingh I; Yala S; Tretiakova M; Arif Q; Hembrough T; Brand TM; Wheeler DL; Husain AN; Vokes EE; Bharti A; Salgia R
    Mol Cancer Ther; 2014 Mar; 13(3):576-84. PubMed ID: 24327519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for mitomycin and irinotecan use in advanced breast cancer.
    Xu Y; Shapiro CL
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):25-8. PubMed ID: 12800602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
    Mrozek E; Kolesar J; Young D; Allen J; Villalona-Calero M; Shapiro CL
    Ann Oncol; 2008 Aug; 19(8):1417-1422. PubMed ID: 18407955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity.
    Rømer MU; Jensen NF; Nielsen SL; Müller S; Nielsen KV; Nielsen HJ; Brünner N
    Scand J Gastroenterol; 2012 Jan; 47(1):68-79. PubMed ID: 22171973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer].
    Okubo S; Kurebayashi J; Sonoo H; Hirono M; Nomura N; Udagawa K; Yamamoto Y; Ikeda M; Nakashima K; Tanaka K
    Gan To Kagaku Ryoho; 2003 Oct; 30(10):1441-5. PubMed ID: 14584275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.